Westmont

Researchers are evaluating the use of semiconductor fabric sleeves in patients undergoing Anterior Cruciate Ligament (ACL) or ACL with Meniscus surgery. The study aims to find out whether these semiconductor sleeves improve functional outcomes and if they help patients recover faster compared to a placebo sleeve without semiconductor material. Participants will be randomly assigned to wear either semiconductor embedded fabric sleeves or non-semiconducting fabric sleeves as a placebo. They will wear the leg sleeve for 4 weeks following surgery and then a knee sleeve for the subsequent 12 weeks, totaling 4 months of sleeve use. The study compares these two types of sleeves to assess their effects on recovery. During the study, participants will complete patient-reported outcome surveys and have their range of motion assessed after 1 year. The researchers will monitor functional improvements and track recovery progress through both patient feedback and clinical measurements. Participants must adhere to the follow-up schedule and study guidelines throughout the study duration.

Researchers are evaluating the combination of the investigational drug PF-06821497 (mevrometostat) with enzalutamide compared to enzalutamide alone in men with metastatic castration-resistant prostate cancer (mCRPC) who have not previously received androgen receptor signaling inhibitors (ARSi) or abiraterone. This global, multicenter Phase 3 study focuses on participants whose cancer has progressed despite androgen deprivation therapy (ADT) or first-generation anti-androgens but who have not started other systemic anti-cancer treatments for mCRPC. The study excludes those with prior treatment using enzalutamide, darolutamide, apalutamide, or abiraterone in any setting, though chemotherapy is allowed in the hormone-sensitive setting. The study includes a Screening Phase, followed by randomization where participants are assigned equally to one of two groups: one receiving PF-06821497 plus enzalutamide, and the other receiving placebo plus enzalutamide. All treatments are taken orally on a continuous basis. After the treatment phase, participants enter a Safety Follow-up and a Long-Term Follow-up period to monitor ongoing effects. Participants will undergo assessments during the study to evaluate radiographic progression-free survival over about three years. Researchers will collect imaging data such as bone scans and CT or MRI scans to monitor disease progression. Additional evaluations include performance status, life expectancy assessments, and safety monitoring for adverse events. The study duration spans from screening through treatment and follow-up phases to gather comprehensive data on the combination therapy's impact on mCRPC.